Health care stocks were mixed pre-bell Friday as the iShares Biotechnology ETF (IBB) was 0.1% higher and the Health Care Select Sector SPDR Fund (XLV) was down 0.2% recently.
UnitedHealth Group (UNH) and Amedisys (AMED) extended the deadline for closing their $3.3 billion merger agreement as the US Department of Justice scrutinizes the deal, a filing showed. Amedisys shares rose past 4% premarket.
Takeda Pharmaceutical (TAK) shares were up over 1% after the company said the Japanese Ministry of Health, Labor and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia.
Exicure (XCUR) shares advanced by about 9% after the company said it signed a memorandum of understanding with GPCR Therapeutics for the acquisition of the South Korean company's US subsidiary, GPCR USA, to advance its growth as a clinical-stage biotech firm.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。